(INNS)
SIREXATAMAB(INND)
SIREXATAMAB(INNC)
IMMUNOGLOBULIN G4-KAPPA, ANTI-[HOMO SAPIENS DKK1 (DICKKOPF WNT SIGNALING PATHWAY INHIBITOR 1, SK, DKK- 1)], HUMANIZED MONOCLONAL ANTIBODY; GAMMA4 HEAVY CHAIN HUMANIZED (1-445) [VH (HOMO SAPIENS IGHV3-7*01 (90.8%) -(IGHD) -IGHJ3*02 (92.9%) M123>T (114), CDR-IMGT [8.8.12] (26-33.51- 58.97-108)) (1-119)-HOMO SAPIENS IGHG4*01, G4V5 H P10, G4V4 CH2 A1.3, A1.2 (CH1 (120-217), HINGE 1-12 S10>P (227) (218-229), CH2 F1.3>A (233), L1.2>A (234) (230-339), CH3 (340-444), CHS K2>DEL (445)) (120-445)], (133-214')-DISULFIDE WITH KAPPA LIGHT CHAIN HUMANIZED (1'-214') [V-KAPPA (HOMO SAPIENS IGKV3- 11*01 (84.2%) -IGKJ4*01 (91.7%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (153), V101 (191) (108'-214')]; DIMER (225-225'':228-228'')-BISDISULFIDE, PRODUCED IN A CHINESE HAMSTER OVARY (CHO)-DERIVED CELL LINE, GLYCOFORM ALFA(WHO)
SIREXATAMABUM(INN)